YuanBen has established R&D centers and clinical trial centers in the United States, Canada and China, forming an innovation system on powerful combination, with close cooperation and appropriate division of labors, and establishing a solid platform for rapid clinical transformation for drugs.

According to the development goals, the company will continue to invest in scientific research and innovation at an annual growth rate of 50% on the basis of the 20 million RMB Yuan research fund invested in 2019-2020.

Adhering to the development concept of "people-oriented", YuanBen constantly introduces talents urgently needed at home and abroad, gives full play to the leading role of core talents, and makes every effort to build talent echelon to promote continuous innovations.

In the aspect of drug innovation research, YuanBen has provided accurate diagnosis of cancer as the guide, focused on the development of therapeutic vaccines, developed a number of international leading, safe and effective cancer drugs affordable to the poverty. Based on this, innovative therapies for more complex diseases including Alzheimer’s disease and NIDDM are planned.